Pyrazole Derivatives Targeting NMDA NR2B Receptors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological and psychiatric disorders associated with NMDA receptor hyperactivity, particularly NR2B receptor activity, lack effective compounds that specifically inhibit NR2B receptors to address these conditions.
Innovation Solution
Development of pyrazole derivatives, specifically compounds of Formula (I) and their pharmaceutically acceptable salts, solvates, or N-oxides, which inhibit NR2B receptors, offering a therapeutic approach for treating disorders related to NMDA receptor hyperactivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for neurological and psychiatric disorders are used, then general symptom management is achieved, but specific inhibition of NR2B receptors is not achieved
Solution Approach 1:
The patent segments the NMDA receptor system by developing compounds that specifically target and inhibit only the NR2B subunit, rather than affecting all NMDA receptors equally. This selective segmentation allows for precise therapeutic intervention in disorders driven by NR2B hyperactivity while preserving other receptor subtypes.
Solution Approach 2:
The invention applies local quality by creating compounds with specific molecular structures (pyrazole derivatives with particular substituent patterns) that confer selective affinity for the NR2B receptor subunit. The local chemical properties of these compounds are tailored to match the specific binding characteristics of NR2B, enabling selective inhibition.
2Object-affected harmful factors
If broad-spectrum NMDA receptor antagonists are used, then general excitotoxicity is reduced, but NR2B-specific pathology is not addressed
Solution Approach 1:
The patent employs parameter changes by systematically varying molecular parameters of the pyrazole core structure, including different substituents at specific positions (R1-R6 groups), to optimize both the potency and selectivity for NR2B receptors. This parameter optimization enables the compound to achieve high NR2B specificity while maintaining effective excitotoxicity reduction.
Solution Approach 2:
The invention creates composite molecular structures by combining the pyrazole core with various aromatic and aliphatic substituent groups. These composite structures integrate multiple functional elements that collectively provide both the binding affinity for NR2B and the selective inhibition profile needed to address NR2B-specific pathology.
Data Source
AI summary
The invention relates to pyrazole derivatives which are NMDA NR2B receptor inhibitors, useful in treating central nervous system diseases.